Ney Carter Borges: Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
”Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis
Stent thrombosis (ST) remains one of the most serious complications following percutaneous coronary intervention (PCI), frequently presenting as acute myocardial infarction (AMI). A contemporary analysis from the National Cardiovascular Data Registry (NCDR) CathPCI registry evaluated trends and outcomes of PCI performed for ST between April 2018 and June 2023. The study included 2,023,032 patients undergoing PCI for AMI, of whom 57,268 cases (2.8%) were attributed to stent thrombosis.
Regarding timing, very late ST (>365 days) represented the largest proportion of cases (49.5%), followed by early ST (≤30 days) at 31.8%, late ST (31–365 days) at 15.4%, and unknown timing in 3.4% of cases. Importantly, the incidence of PCI for ST remained stable over time, despite advances in contemporary PCI techniques, including newer-generation drug-eluting stents, potent P2Y12 inhibitors, and intracoronary imaging.
Clinically, patients with ST tended to be younger, more frequently male, and more likely to present with STEMI, cardiogenic shock, cardiac arrest, and ventricular arrhythmias, reflecting a high-risk population. Compared with PCI for non-ST lesions, PCI performed for ST was associated with significantly worse in-hospital outcomes, including higher rates of major adverse cardiac events (adjusted OR 1.24), all-cause mortality (OR 1.17), recurrent myocardial infarction (OR 1.80), and major bleeding (OR 1.18).
These findings highlight that, despite technological and pharmacologic advances, stent thrombosis remains a rare but high-risk complication of PCI, emphasizing the need for improved preventive strategies, optimized antithrombotic therapy, and procedural techniques to reduce its clinical impact.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Jun 29, 2026, 06:48Christina Pohlman: Anticoagulants and Bone Health – APS Awareness Month Day 23
-
Jun 29, 2026, 06:33Andreas Calatzis: Can Fibrinolysis Sensitivity Be Claimed Without a Reference Standard
-
Jun 29, 2026, 06:25Aliaa Albadri: When a Hair Wash Leads to a Stroke Workup
-
Jun 29, 2026, 06:22Tehreen Parveen: Historical Milestone in Drug Discovery – The Discovery of Aspirin
-
Jun 29, 2026, 06:16Muhammad Sufyan: Deep Vein Thrombosis – Recognizing the Warning Signs
-
Jun 29, 2026, 05:33Janak Sadhu: Uniting for The Stroke-Free Mehsana Initiative
-
Jun 29, 2026, 05:20Deepti Sachan: A Global Exchange Shaping the Future of Transfusion Medicine at ISBT 2026
-
Jun 29, 2026, 04:50Scott Cameron: ACC/AHA Guidance on Acute Pulmonary Embolism Management
-
Jun 29, 2026, 03:10Aryabhatta Sadhu: ABO and Rh Incompatibility In Stem Cell Transplantation